MX2022013885A - Compuestos de metiltioninio para uso en el tratamiento de covid-19. - Google Patents

Compuestos de metiltioninio para uso en el tratamiento de covid-19.

Info

Publication number
MX2022013885A
MX2022013885A MX2022013885A MX2022013885A MX2022013885A MX 2022013885 A MX2022013885 A MX 2022013885A MX 2022013885 A MX2022013885 A MX 2022013885A MX 2022013885 A MX2022013885 A MX 2022013885A MX 2022013885 A MX2022013885 A MX 2022013885A
Authority
MX
Mexico
Prior art keywords
methylthioninium
compounds
covid
treatment
subject
Prior art date
Application number
MX2022013885A
Other languages
English (en)
Inventor
Michael Philip Mazanetz
Claude Michel Wischik
Mohammad Arastoo
Original Assignee
Wista Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wista Lab Ltd filed Critical Wista Lab Ltd
Publication of MX2022013885A publication Critical patent/MX2022013885A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención proporciona métodos para tratar COVID-19 en un sujeto usando compuestos de metiltioninio.
MX2022013885A 2020-05-05 2021-04-30 Compuestos de metiltioninio para uso en el tratamiento de covid-19. MX2022013885A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2006659.3A GB202006659D0 (en) 2020-05-05 2020-05-05 Therapeutic treatments
PCT/EP2021/061481 WO2021224145A1 (en) 2020-05-05 2021-04-30 Methylthioninium compounds for use in the treatment of covid-19

Publications (1)

Publication Number Publication Date
MX2022013885A true MX2022013885A (es) 2022-11-30

Family

ID=71080353

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013885A MX2022013885A (es) 2020-05-05 2021-04-30 Compuestos de metiltioninio para uso en el tratamiento de covid-19.

Country Status (12)

Country Link
US (1) US20230165876A1 (es)
EP (1) EP4146224A1 (es)
JP (1) JP2023524127A (es)
KR (1) KR20230014709A (es)
CN (1) CN116194107A (es)
AU (1) AU2021269001A1 (es)
BR (1) BR112022022527A2 (es)
CA (1) CA3181391A1 (es)
GB (1) GB202006659D0 (es)
MX (1) MX2022013885A (es)
TW (1) TW202200151A (es)
WO (1) WO2021224145A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060264423A1 (en) 2005-05-20 2006-11-23 Bioenvision, Inc. Methylene Blue Therapy of Viral Disease
AU2007231124B2 (en) 2006-03-29 2013-02-21 Wista Laboratories Ltd. 3,7-diamino-10H-phenothiazine salts and their use
CA2827027C (en) 2011-02-11 2019-06-04 Wista Laboratories Ltd. Phenothiazine diaminium salts and their use
AU2017301966B2 (en) 2016-07-25 2022-09-22 Wista Laboratories Ltd. Administration and dosage of diaminophenothiazines
EP4385512A1 (en) * 2018-07-26 2024-06-19 WisTa Laboratories Ltd. Optimised dosage of diaminophenothiazines in populations

Also Published As

Publication number Publication date
AU2021269001A1 (en) 2022-12-08
JP2023524127A (ja) 2023-06-08
CN116194107A (zh) 2023-05-30
CA3181391A1 (en) 2021-11-11
EP4146224A1 (en) 2023-03-15
WO2021224145A1 (en) 2021-11-11
US20230165876A1 (en) 2023-06-01
GB202006659D0 (en) 2020-06-17
BR112022022527A2 (pt) 2022-12-13
KR20230014709A (ko) 2023-01-30
TW202200151A (zh) 2022-01-01

Similar Documents

Publication Publication Date Title
MX2021010193A (es) Azepino-indoles y otros heterociclos para el tratamiento de trastornos cerebrales.
PH12018502355A1 (en) Enzyme inhibitors
MX2024000348A (es) Mavacamten para su uso en el tratamiento de la cardiomiopatia hipertrofica.
SG10201907819WA (en) N-((het)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors,
MX2021008191A (es) Antagonistas del péptido relacionado con el gen de calcitonina (cgrp) para el tratamiento de la irrupción de migraña.
MX2020013808A (es) Antagonista de gremlina-1 para la prevencion y el tratamiento del cancer.
MX2022001004A (es) Inhibidores de enzimas.
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
MX2020008195A (es) Compuestos para el tratamiento del dolor.
MX2019015207A (es) Compuestos para tratar el cancer de ovario.
PH12018502297A1 (en) 9-aminomethyl minocycline compounds and methods of use thereof in urinary tract infection (uti) treatment
PH12020552059A1 (en) Dosing regimen for the treatment of pi3k related disorders
MX2021003903A (es) Terapia combinada para el melanoma.
TN2019000211A1 (en) Antitumoral compounds
MX2023008193A (es) Procedimientos para tratar el cáncer.
PH12018501943A1 (en) Pharmaceutical compositions for the treatment of cancer
MX2021009863A (es) Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer.
MX2021006011A (es) Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma.
CR20220071A (es) Composiciones farmacéuticas y métodos para tratar o prevenir la atrofia muscular espinal
JOP20210245A1 (ar) طرق لعلاج الداء النشواني من النوع خفيف السلسلة
MX2022000811A (es) Inhibidores de enzimas.
MX2019004804A (es) Tratamiento para el prurigo nodula.
MX2020012782A (es) Inhibidor de ccr5 para el uso en el tratamiento de cancer.
MX2021003160A (es) Combinaciones de inhibidores de tgfbeta e inhibidores de cdk para el tratamiento de cancer de mama.
MX2021002652A (es) Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares.